• Aortic Valve
    • Antonio Colombo
    • Antonio Colombo: Influence Statistics

      Antonio Colombo

      Antonio Colombo

      Show email address

      IRCCS Humanitas Research Hospital, Rozzano‐Milan, Italy | Invasive Cardiology Unit, Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy. | Department of ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Antonio Colombo:Expert Impact

      Concepts for whichAntonio Colombohas direct influence:Aortic valve,Coronary artery,Stent implantation,Myocardial infarction,Percutaneous coronary,Eluting stents,Coronary intervention,Transcatheter aortic.

      Antonio Colombo:KOL impact

      Concepts related to the work of other authors for whichfor which Antonio Colombo has influence:Coronary artery,Aortic valve,Myocardial infarction,Stent thrombosis,Intravascular ultrasound,Syntax score,Balloon angioplasty.

      KOL Resume for Antonio Colombo


      IRCCS Humanitas Research Hospital, Rozzano‐Milan, Italy


      Department of Cardiology, GVM Care & Research Maria Cecilia Hospital, Cotignola (RA), Italy

      Emo-GVM Centro Cuore Columbus, Milan

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Antonio Colombo is among the top experts in the world.
      Concept World rank
      side‐branch stent #1
      dapt tavi #1
      soft lesion #1
      mitomo #1
      tavr noacs #1
      aspirin versus ticlopidine #1
      patients needing #1
      207543 #1
      thvno #1
      ≥ tavi #1
      p00001 p0001 #1
      3758 patients #1
      aggressive rotational #1
      elective intervention #1
      3 12 microci #1
      bifurcation lesions cto #1
      sophos #1
      btav tav #1
      provisional hybrid #1
      biocompatibles #1
      cerebral embolic risk #1
      publication atherectomy #1
      peripheral vessel #1
      buddywire #1
      tavi oldppm #1
      pes female follow #1
      ivus clinical outcomes #1
      follow aged #1
      restenosis rate branch #1
      strut width #1
      “coronary sinus reducer #1
      bvs clinical outcomes #1
      mcrs tavi #1
      mentor trial #1
      elixir desolve #1
      mld branch #1
      month dual antiplatelet #1
      target lesion pes #1
      latest generation stents #1
      nonbicuspid valves #1
      “hybrid” neocarina #1
      intraocclusion injection #1
      branch restenosis rate #1
      revalving #1
      gadoliniumbased iodinatedbased #1
      stents angioplasty #1
      incidence major #1
      new tokyo #1
      guided heparin administration #1
      interventional atherectomy ultrasonography #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Antonio Colombo

      KOL-Index: 27690

      BACKGROUND: The Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox (MATRIX) programme was designed to assess the comparative safety and effectiveness of radial versus femoral access and of bivalirudin versus unfractionated heparin with optional glycoprotein IIb/IIIa inhibitors in patients with the whole spectrum of acute coronary syndrome undergoing invasive management. Here we describe the prespecified final 1-year outcomes of the ...

      Known for Femoral Access | Acute Coronary Syndrome | Unfractionated Heparin | Coronary Angiography | Radial Versus
      KOL-Index: 24158

      BACKGROUND: We report the 5-year results of the SYNTAX trial, which compared coronary artery bypass graft surgery (CABG) with percutaneous coronary intervention (PCI) for the treatment of patients with left main coronary disease or three-vessel disease, to confirm findings at 1 and 3 years.

      METHODS: The randomised, clinical SYNTAX trial with nested registries took place in 85 centres in the USA and Europe. A cardiac surgeon and interventional cardiologist at each centre assessed ...

      Known for Coronary Disease | Pci Cabg | Syntax Trial | Bypass Graft | Patients Macce
      KOL-Index: 23164

      BACKGROUND: The anatomical SYNTAX score is advocated in European and US guidelines as an instrument to help clinicians decide the optimum revascularisation method in patients with complex coronary artery disease. The absence of an individualised approach and of clinical variables to guide decision making between coronary artery bypass graft surgery (CABG) and percutaneous coronary intervention (PCI) are limitations of the SYNTAX score. SYNTAX score II aimed to overcome these ...

      Known for Syntax Score | Patients Cabg | Coronary Artery | 4year Mortality | Bypass Surgery
      KOL-Index: 21457

      BACKGROUND: We hypothesised that ticagrelor, in combination with aspirin for 1 month, followed by ticagrelor alone, improves outcomes after percutaneous coronary intervention compared with standard antiplatelet regimens.

      METHODS: GLOBAL LEADERS was a randomised, open-label superiority trial at 130 sites in 18 countries. Patients undergoing percutaneous coronary intervention with a biolimus A9-eluting stent for stable coronary artery disease or acute coronary syndromes were randomly ...

      Known for 12 Months | Aspirin Monotherapy | Acute Coronary Syndromes | 2 Years | Primary Endpoint
      KOL-Index: 19975

      BACKGROUND: The aim of this study was to assess anticoagulation with the direct thrombin inhibitor bivalirudin during percutaneous coronary intervention in individuals with moderate and high-risk acute coronary syndromes.

      METHODS: 13,819 individuals in the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial were prospectively randomly assigned to receive heparin (unfractionated or enoxaparin) plus glycoprotein IIb/IIIa inhibitors, bivalirudin plus glycoprotein ...

      Known for Glycoprotein Iib | Inhibitors Bivalirudin | Acute Catheterization | Coronary Intervention | Composite Ischaemia
      KOL-Index: 19803

      CONTEXT: At 30-day follow-up, patients with moderate- and high-risk acute coronary syndromes (ACS) undergoing early invasive treatment in the ACUITY trial with bivalirudin monotherapy vs heparin plus glycoprotein (GP) IIb/IIIa inhibitors had noninferior rates of adverse ischemic events with reduced rates of major bleeding. Deferred upstream use of GP IIb/IIIa inhibitors for selective administration to patients undergoing percutaneous coronary intervention (PCI) resulted in a significant ...

      Known for Acuity Trial | Gp Iib | Composite Ischemia | Antithrombotic Strategies | Iiia Inhibitors
      KOL-Index: 19798

      OBJECTIVES: The aim of this study was to evaluate the efficacy of drug-eluting balloons (DEB) compared with paclitaxel-eluting stents (PES) for the reduction of restenosis in small vessels.

      BACKGROUND: DEB have been shown to be effective in the treatment of coronary in-stent restenosis, but data are limited regarding their efficacy in de novo disease.

      METHODS: BELLO (Balloon Elution and Late Loss Optimization) is a prospective, multicenter trial that randomized 182 patients with lesions ...

      Known for Late Loss | Eluting Balloon | Small Coronary | Deb Pes | Paclitaxel Drug
      KOL-Index: 18078

      BACKGROUND: Dual antiplatelet therapy (DAPT) cessation increases the risk of adverse events after percutaneous coronary intervention (PCI). Whether risk changes over time, depends on the underlying reason for DAPT cessation, or both is unknown. We assessed associations between different modes of DAPT cessation and cardiovascular risk after PCI.

      METHODS: The PARIS (patterns of non-adherence to anti-platelet regimens in stented patients) registry is a prospective observational study of ...

      Known for Dapt Cessation | Cardiac Events | Patients Pci | Dual Antiplatelet Treatment | Coronary Intervention
      KOL-Index: 17981

      BACKGROUND: The prospective, multinational, randomized Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial was designed to assess the optimal revascularization strategy between percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), for patients with left main (LM) and/or 3-vessel coronary disease.

      METHODS AND RESULTS: This observational hypothesis-generating analysis reports the results of a prespecified powered ...

      Known for Cabg Pci | Cardiac Surgery | Eluting Stents | Patients Lm Disease | 1 Year
      KOL-Index: 17317

      OBJECTIVES: Surgical mitral repair is the conventional treatment for severe symptomatic functional mitral regurgitation (FMR). Mitraclip therapy is an emerging option for selected high-risk patients with FMR. The aim of this study was to report the outcomes of patients who underwent a surgical mitral repair and Mitraclip therapy for FMR in our experience.

      METHODS: From March 2000 and April 2011, 143 patients with FMR were treated in our institution: 91 patients (63.6%) underwent surgical ...

      Known for Mitraclip Therapy | Surgical Mitral | 1 Year | Ventricular Failure | Patients Fmr
      KOL-Index: 17107

      OBJECTIVES: This study was designed to determine the impact of bivalirudin on 1-year outcomes in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI).

      BACKGROUND: The ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial demonstrated that in moderate- and high-risk ACS patients undergoing PCI, bivalirudin alone compared to unfractionated heparin (UFH) or enoxaparin plus a glycoprotein (GP) IIb/IIIa inhibitor resulted in less ...

      Known for Acute Catheterization | Glycoprotein Iib | Coronary Intervention | Patients Pci | 1 Year
      KOL-Index: 17051

      BACKGROUND: Current guidelines for patients with moderate- or high-risk acute coronary syndromes recommend an early invasive approach with concomitant antithrombotic therapy, including aspirin, clopidogrel, unfractionated or low-molecular-weight heparin, and glycoprotein IIb/IIIa inhibitors. We evaluated the role of thrombin-specific anticoagulation with bivalirudin in such patients.

      METHODS: We assigned 13,819 patients with acute coronary syndromes to one of three antithrombotic ...

      Known for Heparin Bivalirudin | Glycoprotein Iib | Unstable Angioplasty | Acute Coronary Syndromes | Rates Ischemia
      KOL-Index: 16736

      CONTEXT: Traditionally, stent thrombosis has been regarded as a complication of percutaneous coronary interventions during the first 30 postprocedural days. However, delayed endothelialization associated with the implantation of drug-eluting stents may extend the risk of thrombosis beyond 30 days. Data are limited regarding the risks and the impact of this phenomenon outside clinical trials.

      OBJECTIVE: To evaluate the incidence, predictors, and clinical outcome of stent thrombosis after ...

      Known for Successful Implantation | Eluting Stent | Sirolimus Paclitaxel | Incidence Predictors | Clopidogrel Aspirin
      KOL-Index: 16705

      OBJECTIVES: We sought to evaluate at 5 years the occurrence of cardiac death; cardiac death, and/or myocardial infarction (MI); cardiac death, MI, and/or stroke; target vessel revascularization; and major adverse cardiac and cerebrovascular events following percutaneous coronary intervention (PCI) with drug-eluting stent (DES) versus coronary artery bypass graft (CABG) in unprotected left main coronary artery lesions.

      BACKGROUND: Preliminary results at 1 year showed comparable occurrence ...

      Known for Pci Cabg | Cardiac Death | Coronary Artery Bypass | Cerebrovascular Events | Artery Lesions
      KOL-Index: 16594

      BACKGROUND: The placement of stents in coronary arteries has been shown to reduce restenosis in comparison to balloon angioplasty. However, clinical use of intracoronary stents is impeded by the risk of subacute stent thrombosis and complications associated with the anticoagulant regimen. To reduce these complications, the hypothesis that systemic anticoagulation is not necessary when adequate stent expansion is achieved was prospectively evaluated on a consecutive series of patients who ...

      Known for Coronary Stent | Procedure Time | Patients Antiplatelet Therapy | Clinical Follow | Balloon Angioplasty

      Key People For Aortic Valve

      Top KOLs in the world
      Martin B Leon
      aortic valve intravascular ultrasound coronary artery
      John G Webb
      aortic valve cardiogenic shock 1 year
      Michael J Mack
      aortic valve coronary artery united states
      David Craig Miller
      aortic valve mitral regurgitation marfan syndrome
      Lars Georg Svensson
      aortic valve partner trial united states
      aortic stenosis valvular heart disease mitral regurgitation

      IRCCS Humanitas Research Hospital, Rozzano‐Milan, Italy | Invasive Cardiology Unit, Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy. | Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan, Italy. | Humani

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.